Associated Papers
Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
Khalique S et al.
The Journal of Pathology. Clinical Research, 2018
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS et al.
Cancer, 2016
Development and clinical application of an integrative genomic approach to personalized cancer therapy.
Uzilov AV et al.
Genome Medicine, 2016
27245685 (PubMed )
Supplement: 13073_2016_313_MOESM1_ESM.xlsx › S5
Select a paper to view details